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Abstract
Aging is a major risk factor for progression of liver diseases to
hepatocellular carcinoma (HCC). Cellular senescence contri-
butes to age-related tissue dysfunction, but the epigenetic basis
underlying drug-induced senescence remains unclear.macroH2A1,
a variant of histone H2A, is a marker of senescence-associated
heterochromatic foci that synergizes with DNA methylation to
silence tumor-suppressor genes in human ﬁbroblasts. In this
study, we investigated the relationship between macroH2A1
splice variants, macroH2A1.1 and macroH2A1.2, and liver
carcinogenesis. We found that protein levels of both
macroH2A1 isoforms were increased in the livers of very elderly
rodents and humans, and were robust immunohistochemical
markers of human cirrhosis and HCC. In response to the
chemotherapeutic and DNA-demethylating agent 5-aza-deox-
ycytidine (5-aza-dC), transgenic expression of macroH2A1 iso-
forms in HCC cell lines prevented the emergence of a senescent-
like phenotype and induced synergistic global DNA hypo-
methylation. Conversely, macroH2A1 depletion ampliﬁed the
antiproliferative effects of 5-aza-dC in HCC cells, but failed to
enhance senescence. Senescence-associated secretory pheno-
type and whole-transcriptome analyses implicated the p38
MAPK/IL8 pathway in mediating macroH2A1-dependent
escape of HCC cells from chemotherapy-induced senescence.
Furthermore, chromatin immunoprecipitation sequencing
revealed that this hepatic antisenescence state also required
active transcription that could not be attributed to genomic
occupancy of these histones. Collectively, our ﬁndings reveal a
new mechanism by which drug-induced senescence is epige-
netically regulated by macroH2A1 and DNA methylation and
suggest macroH2A1 as a novel biomarker of hepatic senescence
that could potentially predict prognosis and disease progres-
sion. Cancer Res; 76(3); 1–13. 2016 AACR.
Introduction
Hepatocellular carcinoma (HCC) is the sixth most frequently
diagnosed cancer and the second leading cause of cancer-related
death worldwide. Prognosis is poor, as only 10% to 20% of
patients with HCC are eligible for surgery; without surgery, the
expected survival is less than 6months (1). Aging is themajor risk
factor for HCC, which is often triggered by the metabolic syn-
drome and nonalcoholic fatty liver disease (NAFLD), along with
the insurgence of cirrhosis (2). In agreement with the inﬂamm-
aging theory, in which aging accrues inﬂammation, old age seems
to favor the progression of liver diseases toward HCC (2). In the
absence of disease, the liver possesses a unique regenerative
1Institute for Liver and Digestive Health, Royal Free Hospital, Uni-
versity College London, London, United Kingdom. 2Division of Inter-
nal Medicine, Department of Medical Sciences, IRCCS "Casa Sollievo
della Sofferenza" Hospital, San Giovanni Rotondo, Italy. 3Bioinfor-
matics Unit, IRCCS "Casa Sollievo della Sofferenza"—Mendel Labo-
ratory, Rome, Italy. 4Department of Experimental Biomedicine and
Clinical Neurosciences, Section of Human Anatomy, University of
Palermo, Palermo, Italy. 5Gastroenterology Unit, IRCCS "Casa Sol-
lievo della Sofferenza" Hospital, San Giovanni Rotondo, Italy. 6School
of Biological and Chemical Sciences, Queen Mary University of
London, London, United Kingdom. 7Department of Gene Technolo-
gy,Tallinn University of Technology (TTU), IVEX Lab,Tallinn, Estonia.
8Department GF Ingrassia, University of Catania, Catania, Italy.
9Department of Cell Biology, University Medical Center Groningen,
Groningen, the Netherlands. 10Centre for Education and Research on
Aging (CERA) and the ANZAC Research Institute, Concord RG
Hospital, University of Sydney, Sydney, Australia. 11Department of
Molecular Biology, Cell Biology and Biochemistry, Brown University,
Providence, Rhode Island. 12Institute for Predictive and Personalized
Medicine of Cancer, Campus Can Ruti, Badalona, Spain. 13Josep
Carreras Institute for Leukaemia Research, Campus ICO—HGTP,
Campus Can Ruti, Badalona, Spain. 14Euro-Mediterranean Institute
of Science and Technology (IEMEST), Palermo, Italy. 15School of
Science and Technology, Nottingham Trent University, Nottingham,
United Kingdom.
Note: Supplementary data for this article are available at Cancer Research
Online (http://cancerres.aacrjournals.org/).
V. Pazienza and M. Vinciguerra contributed equally to this article.
Corresponding Author: Manlio Vinciguerra, University College London, Row-
land Hill Street, London NW3 2PF, UK. Phone: 0044-77-2548-8381; Fax: 0044-
20-7433-2852; E-mail: m.vinciguerra@ucl.ac.uk
doi: 10.1158/0008-5472.CAN-15-1336
2016 American Association for Cancer Research.
Cancer
Research
www.aacrjournals.org OF1
Research. 
on January 18, 2016. © 2016 American Association for Cancercancerres.aacrjournals.org Downloaded from 
Published OnlineFirst January 15, 2016; DOI: 10.1158/0008-5472.CAN-15-1336 
capacity and preserved functional performance during aging (2).
Nevertheless, the aging process increases the risk of hepatic
functional and structural impairment and metabolic risk. In this
respect,mousemodels ofmetabolic syndromewithNAFLD reveal
features of accelerated aging, impaired regeneration, and an
increased incidence ofHCC(2, 3). Interventions to clear senescent
hepatocytes in a neoplastic-prone tissuemicroenvironment delay
the emergence of HCC in rats (4). Cellular senescence can thus
regulate tumor suppression, as well as contribute to age-related
loss of tissue function through the secretion of multiple proin-
ﬂammatory molecules, such as IL6 and IL8, as part of a senes-
cence-associated secretory phenotype (SASP; ref. 5). Moreover,
changes in nuclear chromatin structure that occur during senes-
cence are highlighted by the formation of punctate and visible
DNA foci in 40,6-diamidino-2-phenylindole (DAPI)–stained
senescent cells, known as senescence-associated heterochromatin
foci (SAHF; ref. 5). In vertebrates, histone variants provide con-
tinuous regulation of nucleosome turnover across the entire life-
span of the organism, in addition to being expressed in terminally
differentiated cells, and they are a chief cellular strategy to regulate
transcription and cellular metabolism. Speciﬁcally, the histone
H2A variantmacroH2A1 is enriched in SAHF of senescent human
ﬁbroblasts (5), but its mechanistic role in cellular senescence is
poorly understood. macroH2A1 is composed of a domain 66%
homolog to histone H2A, and it stands out because of its unique
structure, whereby a C-terminal linker connects the histone fold
domain to a macro domain. This domain protrudes from the
compact structure of the nucleosome, likely affecting the function
and organization of the surrounding chromatin, and is conserved
in multiple functionally unrelated proteins throughout the ani-
mal kingdom.macroH2A1 exists as two alternatively exon-spliced
isoforms, macroH2A1.1 and macroH2A1.2, which bind in vitro
with different afﬁnities to O-acetyl-ADP-ribose (OAADPR), a
small metabolite produced by the protein/histone deacetylase
SIRT1 (6). Historically, macroH2A1 has been implicated in X
chromosome inactivation and transcriptional repression: this
view has recently been challenged by reports that have linked
macroH2A proteins to signal-induced gene activation (7–9).
macroH2A1 isoforms have taken center stage in the plasticity of
stem cell differentiation and in the pathogenesis of many cancers,
providing an exciting, yet poorly understood, link to metabolism
and nutrients (10, 11).
In the liver, genome binding and transcriptomic studies using
knock-out (KO)mice have shown thatmacroH2A1participates in
the pathogenesis of NAFLD and fat-induced obesity (12–18).
Moreover, increased expression of macroH2A1 isoforms in the
livermight be used as a diagnostic andprognosticmarker forHCC
(3). In the aging murine and primate livers, we observed an
increased age-associated localization of macroH2A1 to regions
of pericentromeric heterochromatin (19). It is, however,
unknown whether increased expression of macroH2A1 during
aging could favor the onset of HCC, which is characterized by
profound epigenetic alterations, such as promoter-speciﬁc hyper-
methylation and global DNA hypomethylation (20). Hypo-
methylating agent 5-aza-deoxycytidine (5-aza-dC, decitabine)
and its derivatives inhibit DNA methyltransferases proteins and
are chieﬂy used for the treatment of nonsolid malignancies;
however, they also exert antitumor effects in HCC cells by induc-
ing senescence (21–24). In human ﬁbroblasts, macroH2A1 deﬁ-
ciency combined with 5-aza-dC treatment activates tumor-sup-
pressor genes and inhibits cell proliferation (25).
The aim of this study is to investigate the interplay between
macroH2A1 isoforms and DNA methylation during "healthy"
liver aging and hepatic carcinogenesis, using aged and KO rodent
models, macroH2A1-isoform speciﬁc transgenic HCC cell lines,
and human liver tissues.
Amodel emerged where macroH2A1marks but does not affect
physiologic hepatic senescence. In the presence of HCC-associ-
ated or chemotherapy-induced DNA hypomethylation, high
levels of macroH2A1 might instead favor HCC progression
through a distinct p38 MAPK/IL8-dependent mechanism.
Materials and Methods
Animals
All mice in C57/BL6 background were housed in a clean,
temperature-controlled mouse facility on a 12-hour light/dark
cycle on a standard diet. Liver tissues from young (3 months)
and old (30 months) animals were provided by the European
Molecular Biology Laboratory, Monterotondo, Italy. Harvesting
procedures were approved by the local Ethical Committee (Mon-
terotondo, Italy) and were in accordance with national and
European regulations.macroH2A1KOmicewere kindly provided
by Professor John Pehrson (University of Pennsylvania, Philadel-
phia, PA; ref. 26). Aged macroH2A1 KOmice were produced and
housed at Brown University in a speciﬁc pathogen-free Associa-
tion for Assessment and Accreditation of Laboratory Animal
Care–certiﬁed barrier facility. Heterozygous animals were bred,
and macroH2A1 þ/þ and / littermates were retained for
further analysis. All procedures were approved by the Brown
University Institutional Animal Care and Use Committee. Ani-
mals were euthanized using isoﬂuorane anesthesia, followed by
cervical dislocation. Liver tissuewas rapidly removed,ﬂash-frozen
in liquid nitrogen or embedded in optimal cutting temperature
compound, and stored at 80C.
Human biopsies and histology
Liver specimens were obtained from patients undergoing clin-
ically indicated hepatic biopsies (27), with appropriate institu-
tional ethical approval and patient consent and in accordance
with the Code of Ethics of the World Medical Association (Dec-
laration of Helsinki). Liver parafﬁn-embedded sections (4-mm-
thick, 10 per condition) were stained with hematoxylin & eosin
(H&E) and Masson's trichrome for histologic evaluation, as
described previously (3, 28). Diagnostic classiﬁcation of NAFLD
and ﬁbrosis/cirrhosis was performed using a semiquantitative
scoring system that grouped histologic features into broad cate-
gories (steatosis, hepatocellular injury, portal inﬂammation,
ﬁbrosis, and miscellaneous features; ref. 29). Human healthy
liver samples from four old (72–81 years old) and four young
(33–48 years old) healthy subjects were obtained from OriGene.
Immunohistochemistry and X-gal staining
Sections from human liver specimens were processed by Mas-
son trichrome staining for histologic evaluation. Immunostaining
on human biopsies and murine livers was performed using the
iVIEW DAB Detection Kit for the Ventana BenchMark XT–auto-
mated slide stainer. Primary antibodies for macroH2A1.1 and
macroH2A1.2 were previously generated (3). Anti-5-Methylcyto-
sine (33D3) antibody was obtained from Active Motif (cat. no.
39649); anti-GLB1/Beta-Galactosidase Antibody (clone 5H2)
IHC-plus LS-B10217 was obtained from LSBio. macroH2A1.1,
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macroH2A1.2, and anti-GLB1 primary antibodies were diluted
1:100; anti-5-Methylcytosine primary antibody was diluted
1:1,000. Positive and negative controls were run concurrently.
Means of triplicate counts were used for statistical analyses. For X-
Gal staining of murine livers, frozen sections of 5-mm thickness
were used and processed as previously described (30). Slides were
counterstained with eosin, mounted with aqueous medium, and
observed with an optical microscope (Nikon ECLIPSE Ni) con-
nected to a digital camera (DS-Fi2). The percentage of blue
staining, indicating b-galactosidase activity, was calculated in
10 random high-power ﬁeld (HPF) at 400 magniﬁcation and
expressed as means. Also, after performing quantitative analysis,
the results were expressed in a semiquantitative scale (: 0%; þ:
1%–33%; þþ: 34%–66%; þþþ: 67%–100%). All analyses were
performed in triplicate by three independent pathologists.
Constructs, cell cultures, and proliferation/migration assays
Stable differential expression ofmacroH2A1.1 ormacroH2A1.2
isoforms tagged with GFP in HepG2 and in Huh-7 cells was
achieved by lentiviral transduction. cDNAs encoding macroH2A1
isoforms were placed under the control of a constitutive EF1a
promoter in the HIV1-based self-inactivating lentiviral vector,
modiﬁed to allowexpressionofmacroH2A isoformsasN-terminal
fusions with a monomeric ﬂuorescent protein mTagGFP. Viral
preparations were produced by transient transfection in HEK293T
cells, and concentrated 100-fold by low-speed centrifugation
(6,000 g for 16 hours). HepG2 andHuh-7 cells were transduced
with virus at multiplicity of infection > 10 for 24 hours in
the presence of 4 mg/mL Polybrene. Stably transduced cell popula-
tions were established and used in subsequent experiments with-
out clonal selection. To generate appropriate controls, cells
were also stably transduced with the empty vector (expressing
only mTagGFP) and maintained in similar culture conditions
to macroH2A1-expressing cells. For knock-down experiments,
HepG2were transducedwith retroviral macroH2A-speciﬁc shRNA
cassettes (31). Transient transfection of macroH2A1 isoforms in
mouse HCC Hepa1-6 cells was carried out as described (17).
HepG2 and Huh-7 cells were treated for 72 hours with 12
mmol/L of 5-aza-dC (decitabine; Sigma). For p38 MAPK activity
inhibition and IL8 receptor blockade, cells were concomitantly
treated with 10 mmol/L SB202190 or 10 mmol/L SB265610 (Sig-
ma), respectively. Cell migration and cell proliferation were
assessed by wound-healing assay and by MTT assay respectively
as previously described (17, 32).
SASP analyses
sICAM, IL1b, IL6, and IL8 levels were assessed in HepG2 and
Huh-7 cell supernatants, upon treatment with 5-aza-dC and or
p38 MAPK/IL8 pathway chemical inhibitors, using a customized
human MILLIPLEX MAP (multi-analyte panels) Luminex system
(Merck Millipore; ref. 12), according to the manufacturer's
instructions.
b-galactosidase assay
The Senescence b-Galactosidase Staining Kit (Cell Signaling
Technology; #9860) was used in HepG2 and in Huh-7 cells to
evaluate b-galactosidase activity at pH 6, a known characteristic of
senescence, according to the manufacturer's instructions.
DNA methylation assay (LUMA)
LUMAwas used to quantify genome-widemethylation levels in
cell lines andmouse liver (33). GenomicDNAwas extracted using
a commercial kit (Qiagen). LUMA measures the percentage of
global methylation using the ratio of DNA cleavage by methyl-
ation-sensitive (HpaII) and methylation-insensitive (MspI)
restriction enzymes, followed by polymerase extension assay by
pyrosequencing to determine cleavage. The LUMA method was
validatedusingDNAcontrols of knownhumanDNAmethylation
status. Genome-wide methylation was expressed as a percentage
as previously described (33).
Gene expression
Total RNAwas isolated from livers of mice or cells using TRIzol
(Invitrogen) and quantiﬁed using NanoDrop 1000 spectropho-
tometer (Thermo Scientiﬁc). After RNA quality veriﬁcation, 1 to 2
mg was used to prepare cDNA. In Hepa1-6 HCC cells, Cellular
Senescence RT2 Proﬁler PCR Array proﬁles were assessed follow-
ing the manufacturer protocol (SABioscience). Quantitative PCR
was performed using SYBR Green (SIGMA) in an ABI-PRISM
qPCR cycler (Applied Biosystems), as described previously
(34). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
transcript was used as internal control for normalization using
the 2-DDCT method. Primer sequences were as follows: GAPDH,
Forward CATGGCCTTCCGTGTTCCTA, Reverse GCGGCAC-
GTCAGATCCA; GLB1, Forward TTTACGTGGGCAACTTCTC,
Reverse TACTTGACCCTTGGACCAC.
Western blot
Chromatin and nuclei protein fractions from macroH2A1.1-
GFP, macroH2A1.2-GFP, and GFP transgenic HepG2 and Huh-7
cells were isolated (35). Cell pellets were suspended in buffer A
(10 mmol/L HEPES, 10 mmol/L KCl, 1.5 mmol/L MgCl2, 340
mmol/L sucrose, 10% glycerol, 1mmol/L DTT), incubated on ice,
and centrifuged at 1,300  g at 4C for 5 minutes to separate
supernatant from nuclei. Nuclei fractions were washed once and
lysed for 30 minutes in buffer B (3 mmol/L EDTA, 0.2 mmol/L
EGTA, 1 mmol/L DTT) and centrifuged at 1,700  g at 4C for 5
minutes to separate the supernatant (nuclei) from the pellet
(chromatin). Cytoplasmic and nuclear protein extraction from
rodent liver parenchyma and hepatoma cells, and immunoblot-
ting analyses were performed as described previously (3). The
histone fraction was enriched using acid extraction and 2,2,2-
trichloroacetic acid precipitation. Primary antibodies were
obtained from Activ Motif (macroH2A1.1 and macroH2A1.2),
Cell Signaling Technology [phospho-p38 MAPK (Thr180/
Tyr182), p38 MAPK, phospho-MSK1 (Thr581), MSK1, phos-
pho-ATF2 (Thr71), and ATF2], and Abcam (GFP, PCNA). Anti-
bodies against histone H3 (Activ Motif), GAPDH (Cell Signaling
Technology), and b-actin (Santa Cruz Biotechnology) were used
to normalize protein levels.
Chromatin immunoprecipitation sequencing and RNA-
sequencing
For both chromatin immunoprecipitation sequencing (ChIP-
Seq) and RNA-sequencing (RNA-Seq), Genomix4life S.r.l. per-
formed sample quality control by next-generation sequencing.
ChIP was performed with a modiﬁed protocol as described
previously (36). Chromatin complexes were lysed, extracted,
digested with micrococcal nuclease (MNase), immunoprecipi-
tated (using 4 mg of anti-GFP antibody, ab290; Abcam), and
reverse crosslinked. DNA fragments (200 to 1,000 bp) were
then cleaned up and eluted using the components of the Pierce
Agarose ChIP Kit, ChIP-Grade Protein A/G Plus Agarose and
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Proteinase K (Pierce). Primer sequences for positive controls of
macroH2A1 isoform binding to chromatin in HepG2 cells were
LAMA5_-2.8K_F: AGAATGCCCCCACCCTAC, LAMA5_-2.8K_R:
TCCCAAGGTCAGGAGTTCAC; PTPRN_-199_F: TGTAAAG-
CACCTTGGAGACTG, PTPRN_-39_R: CAGAGAGCACAGCAG-
GAGAG. For RNA-Seq, total RNA was extracted from GFP-,
macroH2A1.1-GFP, or macroH2A1.2-GFP transgenic HepG2
cell lines with TRIzol Reagent (Invitrogen). Indexed libraries
were prepared from 2 mg/ea puriﬁed RNA with the TruSeq Total
Stranded RNA Sample Prep Kit (Illumina) according to the
manufacturer's instructions. Libraries were quantiﬁed using the
Agilent 2100 Bioanalyzer (Agilent Technologies) and pooled so
that each index-tagged sample was present in equimolar
amounts; the ﬁnal concentration of the pooled samples was
2 nmol/L. Pooled samples were then subjected to cluster
generation and sequencing using an Illumina HiSeq 2500
System (Illumina) in a 2  100 paired-end format at a ﬁnal
concentration of 8 pmol/L.
Bioinformatics analyses
RNA-Seq and ChIP-Seq raw data (.fastq ﬁles) underwent qual-
ity control analysis using the FastQC software package. Short
reads were discarded, trimmed, or adapter-cleaned where neces-
sary. Transcripts were assembled by aligning around 30 million
reads per sample toward the hg19 reference genome by Bowtie2.
Uniquely mapped reads that fell within each feature of interest
were counted and RPKM normalized. Twenty million reads for
each ChIP-seq experiment were mapped against hg19 by Bowtie.
A peak calling strategy implemented in the PartekGenomics Suite,
which was set to tolerate broadly spreading and weaker patterns,
was used to predict the regions of the genome where the ChiPed
histone was bound. Differentially expressed and differentially
bound genes were subjected to in-silico functional enrichment
analysis by QIAGEN's Ingenuity Pathway Analysis. Functions and
pathways were considered signiﬁcantly over-represented if P
values were <0.05. Genes of relevant pathways were marked with
colors to represent their expression directions.
Statistical analyses
The RNA-Seq study was designed with a sample size of 14 and
conferred a power (1-beta) of 0.8, when the signiﬁcance thresh-
old (alpha) was set at 0.05. We tolerated less than 5% of false
positives and considered only genes with at least a 1.5-fold
difference (FDR-corrected P value <0.05). Differential expres-
sion between genes was determined by two-way ANOVA in the
Partek Genomics Suite, and any random batch effects were
minimized using the Batch Effect Removal tool of Partek.
One-tailed binomial tests were used to calculate P values, which
compared each sample with their respective reference (GFP) in
the ChIP-Seq experiment. A low P value meant there were
signiﬁcantly more reads in the sample than in the reference
sample. The scaled change in intensity of each signal was com-
paredwith the reference sample. The changewas scaled by a ratio
of the number of reads for each sample on a per-chromosome
basis. A scaled change >1 indicated more enrichment in
the sample than in the reference. The whole procedure of
functional enrichment analysis was based on prior calculation
of the activation z-scores, which infer the activation states of
predicted transcriptional regulators, functions, and pathways.
To confer solidity to the analysis, we considered z-scores > 2
(minimum activation threshold) and < 2 (minimum inhibi-
tion threshold).
Results were expressed as mean  SE. Comparisons between
means were made by appropriate Student t tests. Differences of
proportions were assessed by one-tailed c2 tests. Differences were
considered as signiﬁcant when P < 0.05.
Results
Increased levels of macroH2A1 isoforms in old livers and in
human HCC are associated with b-galactosidase expression
Murine hepatic expression ofmacroH2A1.1 andmacroH2A1.2
increases from newborn to adult age (26). We detected signiﬁ-
cantly increased expression of macroH2A1 isoforms (P < 0.01 for
macroH2A1.1 and P < 0.001 for macroH2A1.2, respectively) in
the liver of old (30 months) compared with young (3 months)
mice (Fig. 1A). Strikingly, in healthy humans, the proportion of
nuclei that were immunopositive for macroH2A1 isoforms was
signiﬁcantly higher in the livers of old versus young individuals
(macroH2A1.1: 45.2% 2.4% in old vs. 36.5% 1.5% in young,
respectively, P < 0.05; macroH2A1.2: 56.2%  2.9% in old vs.
36.4%  2.4% in young, respectively, P < 0.05; Fig. 1B and C).
Hepatocyte nuclei fromolder subjects were larger than in younger
subjects (Fig. 1B and C), most likely reﬂecting liver cell polyploi-
dy, which indicates terminal differentiation and senescence. Con-
sistent with previous studies (3), hepatocyte immunopositivity
for macroH2A1.1 and macroH2A1.2 was signiﬁcantly higher in
viral cirrhosis and HCC compared with healthy young controls
(Fig. 1B and C). A signiﬁcantly higher number of cells immuno-
positive for b-galactosidase (b-gal), a key marker of cellular
senescence, paralleled the severity of liver disease (control <
cirrhosis < HCC) in humans, as demonstrated by H&E and
Trichrome staining (Fig. 2A–D). Taken together, these ﬁndings
demonstrate that hepatic expression of macroH2A1 isoforms
increases with healthy aging and during liver cirrhosis and HCC,
and this is paralleled by the growing expression of the senescence
marker b-gal.
Global DNA hypomethylation in HCC but not in old livers
Global changes in DNA methylation may play a pleiotropic
role during aging and age-related pathologies, such as cancer. To
investigate this, we assessed global genomic DNAmethylation in
the liver using LUMA. The median LUMA genome-wide methyl-
ation was similar, approximately 70%, in liver from old (30
months old) and young (3 months) mice (Fig. 3A). Moreover,
we did not detect differences in immunopositivity for cytosine-5
methylation in liver samples from old versus young humans (Fig.
3B and C). Global genomic DNA hypomethylation is observed
along the liver disease spectrum (20). Accordingly, nuclear immu-
nopositivity for cytosine-5 methylation was decreased in liver
biopsies fromHCC patients compared with cirrhotic and healthy
(young and old) controls (Fig. 3B and C). Furthermore, we
compared hepatic DNA methylation levels of patients with HCC
and cirrhosis with those of controls in four major datasets from
the Gene Expression Omnibus databank (GSE44970, GSE56588,
and GSE60753) and from The Cancer Genome Atlas (TCGA; Fig.
3D). The proportion of signiﬁcantly differentially methylated
genes in each dataset indicated signiﬁcantly higher DNA hypo-
methylation in HCC than in cirrhosis. Altogether, our experimen-
tal and in-silico analyses show that hepatic expression of
macroH2A1 isoforms correlates with DNA hypomethylation
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during the progression of HCC and cirrhosis, but not during
healthy aging.
Ablation of macroH2A1 has no effect on age-dependent
hepatocyte senescence and DNA methylation
We used whole-body KO mice for macroH2A1 (12) to inves-
tigate age-dependent hepatocyte senescence and DNA methyla-
tion. We stained the livers of 21.4- to 23.3-month-old
macroH2A1 KO mice and aged-matched wild-type littermates
for senescence-associated X-gal staining. Therewere nodifferences
between the two genotypes (Supplementary Fig. S1A and S1B).
Young, 3-month-old, mice of either genotype were negative for X-
gal staining (data not shown). Furthermore, the levels of positivity
for cytosine-5 methylation in the liver of old macroH2A1 KO
versus wild-type mice were comparable (Supplementary Fig. S1C
and S1D). These data suggest that genetic ablation ofmacroH2A1
has no effect on chief markers of hepatocyte senescence and DNA
methylation during physiologic aging.
macroH2A1 isoforms synergize with 5-aza-dC–induced global
DNA hypomethylation and display protection against 5-aza-
dC–dependent senescence-like phenotype in HCC cells
Promoter DNAhypermethylation and heterochromatinization
are events frequently leading to tumorigenesis (37). Inﬁbroblasts,
knockdown of macroH2A1 synergizes with 5-aza-dC–induced
DNA demethylation and decreases cell proliferation (25). To
investigate if macroH2A1 isoforms synergize with 5-aza-dC–
induced global DNA hypomethylation and display protection
against 5-aza-dC–dependent senescence, we generated lentiviral-
mediated stable HepG2 and Huh-7 cell lines transgenic for GFP,
macroH2A1.1-GFP, or macroH2A1.2-GFP (Fig. 4). Bands at a
molecular weight of approximately 70 KD, corresponding to the
sum of GFP and macroH2A1 molecular weights, were detected
upon nuclear/chromatin fractionation by immunoblotting, indi-
cating amoderate increase in its expression levels (Fig. 4A andD).
H3 served as a marker for the chromatin fraction, PCNA as a
marker of both nuclear and chromatin fractions, and GAPDH as a
negative marker to exclude cytoplasmic contamination. Cells
transgenic for macroH2A1.1-GFP or macroH2A1.2-GFP were
viable and morphologically indistinguishable from GFP trans-
genic cells, and 5-aza-dC did not alter the endogenous expression
levels of macroH2A1.1 and macroH2A1.2 in HepG2 and Huh-7
cells (Fig. 4B and E). As expected, LUMA assay revealed an
approximately 25% and 40% decrease in global DNA methyla-
tion in control GFP-expressing HepG2 and Huh-7 cells, respec-
tively (Fig. 4C and F). Transgenic expression of either
macroH2A1.1-GFP or macroH2A1.2-GFP synergized with 5-
aza-dC and induced greater DNA hypomethylation: of approxi-
mately 40% to 50% inHepG2 cells, and of approximately 60% to
75% in Huh-7 cells, compared with respective untreated control
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macroH2A1.1 and macroH2A1.2
expression in the whole liver of: old
versus young mice (A); old and young
healthy controls, patients with
cirrhosis and HCC (B). Age is indicated
in A and B (mth, months; yo, years
old). A, left, representative blots of 3 to
4 animals per age group. Histone H3
was used as a loading control; right,
quantitative measurement of
macroH2A1.1 and macroH2A1.2
associated signals by densitometry.
Values were normalized to H3 levels
and expressed as a percentage of
young (3 mth). B, representative
pictures of immunostaining
performed for macroH2A1.1 and
macroH2A1.2 in human liver samples
from a young (33 years old) versus an
old (81 years old) healthy subject
(n ¼ 6 per condition, 33–48 years old
! young range, 72–81 years old! old
range) and in human liver samples
with viral cirrhosis or HCC (n ¼ 10 per
condition). All nuclei of tumor cells
were positive for either macroH2A1.1
or macroH2A1.2. Positivity of
hepatocytes from cirrhotic livers was
intermediate. C, data are expressed as
mean  SE of 10 blindly chosen and
evaluated HPF. Bar, 100 mm. A–C,
 , P < 0.05;  , P < 0.01; and
 , P < 0.001.
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cells (Fig. 4C and F). HepG2 and Huh-7 cell lines treated with
12 mmol/L 5-aza-dC for 72 hours exhibited a characteristic ﬂat-
tenedmorphology and positive staining for the senescence mark-
er b-galactosidase (Fig. 5A and E), compared with untreated cells
(Supplementary Fig. S2). Imaging-assisted quantitative analyses
revealed that approximately 70% of GFP-expressing HepG2 cells,
and approximately 80% of GFP-expressing Huh-7 cells, were
positive for b-galactosidase staining (Fig. 5A, B, E, and F). In
contrast, only approximately 40%and35%ofmacroH2A1.1-GFP
andmacroH2A1.2-GFPHepG2 transgenic cells, and approximate-
ly 60% and 35% of macroH2A1.1-GFP and macroH2A1.2-GFP
Huh-7 transgenic cells, respectively,werepositive (Fig. 5A,B,E, and
F), indicating an antisenescence effect ofmacroH2A1 isoforms. In
the Hepa1-6 mouse HCC cell line, 5-aza-dC treatment induced
a weaker b-gal staining compared with HepG2 and Huh-7
cells (Supplementary Fig. S3). Transient overexpression of
macroH2A1.1-GFP or macroH2A1.2-GFP induced a decrease in
the number of b-gal–positive Hepa1-6 cells, accompanied by an
antisenescence gene expression proﬁle (including decreased
mRNA expression of GLB1, the gene encoding for b-gal), when
compared with control cells (Supplementary Fig. S3A–S3C).
Senescence is characterized by a withdrawal from cell cycle and
decrease in cell proliferation. In this respect, macroH2A1.1-GFP
and macroH2A1.2-GFP transgene-bearing HepG2 and Huh-7
cells displayed a signiﬁcant 2- to 3-fold increase in cell growth
compared with control GFP-expressing cells upon 5-aza-treat-
ment, but not in untreated cells (Fig. 5C and G). Micrograph
analysis of wound closure in scratch assays showed faster cell
migration in both macroH2A1.1 and macroH2A1.2 transgenic
HepG2 and Huh-7 cells upon drug treatment (Fig. 5D and H).
Notably, 5-aza-dC treatment did not induce the appearance of
SAHF in HCC cell lines (data not shown). In vivo, genetic ablation
ofmacroH2A1 did not inﬂuence hepatic senescence (Supplemen-
tary Fig. S1). In vitro, knocking down the whole macroH2A1
gene in HepG2 cells (knockdown, KD) using a stable siRNA
approach achieved a nearly total deletion of macroH2A1.1 and
macroH2A1.2 proteins (Supplementary Fig. S4A): KD cells pro-
liferated slower and showed a slower wound closure in the scratch
assay, compared with control cells (Supplementary Fig. S4B and
S4C). Mirroring in vivo data, we observed no differences in b-gal
staining between control andKD cells following treatmentwith 5-
aza-dC (Supplementary Fig. S4D). Therefore, macroH2A1 iso-
forms facilitate the escape from the 5-aza-dC–induced prosenes-
cent phenotype in HCC cells.
macroH2A1 isoforms induce escape from 5-aza-dC–induced
senescence through p38 MAPK/IL8 signaling in HCC cells
Tumor-suppressor proteins p53, p16, and p21 are involved in
cell-cycle control and are considered master regulators of cell
senescence. However, in our HCC cell models, neither 5-aza-dC
nor macroH2A1 isoform transgenes altered their endogenous
expression levels (data not shown). A central feature of senes-
cence is the induction of the SASP, which implicates a complex
interplay of cytokines and growth factors that are released from
senescent cells (38). 5-aza-dC induces SASP in HepG2 cells (21).
We thus measured the expression of a panel of SASP compo-
nents in the supernatants of HepG2 and of Huh-7 cells treated
with 5-aza-dC. In all cell lines, 5-aza-dC incubation increased
Figure 2.
b-gal expression in the liver of patients
with NAFLD, cirrhosis, and HCC. A and B,
histologic features of liver biopsies from
patients with NAFLD, cirrhosis, and HCC.
A, representative pictures of H&E
staining. B, representative pictures of
trichrome staining. In samples from
patientswith NAFLD,microvesicular and
macrovesicular steatosis are apparent; in
samples from patients with cirrhosis, the
characteristic regenerative nodule
surrounded by scattered lymphocytes
and ﬁbrous connective tissue was more
visible with trichrome staining. In
samples from patients with HCC,
proliferation of hepatocytes and, in the
top left of the trichrome image, the
capsule of the tumor can be observed.
C, representative pictures of b-gal
immunostaining of human liver samples
with NAFLD, cirrhosis, and HCC (n ¼ 10
per condition). All HCC cells were highly
positive; positivity of hepatocytes with
NAFLD was signiﬁcantly lower and was
intermediate in viral cirrhosis. Bar, 100
mm. D, the percentage of b-gal–positive
cells was calculated in 10 blindly chosen
HPF at a magniﬁcation of 400 (left).
Also, after performing quantitative
analysis, the results were expressed in a
semiquantitative scale (0, 0%; 1, 1%–33%;
2, 34%–66%; 3, 67%–100%; right). Data
were expressed as means  SE.
 , P < 0.01 and  , P < 0.001.
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sICAM-1, IL1b, and IL8 levels in the culture supernatants,
whereas it had no effect on IL6 (Fig. 6A and Supplementary
Fig. S5A). Surprisingly, in macroH2A.1- and macroH2A1.2
transgenic cells, IL8 and, to a minor extent, IL1b levels were
signiﬁcantly augmented when compared with control cells (Fig.
6A and Supplementary Fig. S5A). To gain a deeper insight into
the transcriptional proﬁles of 5-aza-dC–treated HCC cells, we
used RNA-Seq. Venn diagrams (Supplementary Fig. S6A)
revealed a low overlap between differentially expressed gene in
macroH2A1.1-GFP and macroH2A1.2-GFP transgenic cells ver-
sus GFP transgenic cells (Supplementary Table S1). Similarly,
the transcriptional proﬁles of macroH2A1 KO versus GFP cells
showed little overlap (Supplementary Fig. S6B). Heatmaps in
Supplementary Fig. S6C and S6D represent the fold changes of
the differentially expressed genes. These listed genes signiﬁcantly
enriched (–log(p-value) >1.3) a number of functions and dis-
eases, including cancer, which macroH2A1.1 and macroH2A1.2
transgenic cells over-represented (Supplementary Fig. S7A; Sup-
plementary Table S2). Ingenuity pathway analysis (IPA)
highlighted genes belonging to the p38 MAPK pathway within
the pathway "cancer," which was signiﬁcantly over-represented
(P < 0.001) in macroH2A1.1-GFP and macroH2A1.2-GFP trans-
genic HepG2 cells (Supplementary Fig. S7B). IPA analysis sug-
gested that p38 activation induced IL8 production (Supplemen-
tary Fig. S7B). To detect the activation status of p38 MAPK in
HepG2 and Huh-7 cells upon 5-aza-dC treatment, we conducted
an immunoblotting analysis of phospho-p38 MAPK (Thr180/
Tyr182) and downstream effectors phospho-MSK1 (Thr581)
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DNA methylation analyses in old
versus young mice (A); old and
young healthy humans with NAFLD,
cirrhosis, and HCC (B and C); and
methylation data mining in cirrhotic
and HCC patients versus control
samples (D). Age is indicated in A
and B (mth, months; yo, years old).
A, proportion of global DNA
methylation analyzed with LUMA
assay is expressed as mean  SE of
three animals per age group.
B, representative pictures of
immunostaining for 5-
methylcytosine in human liver
samples from a young (33-year-old)
versus an old (81-year-old) healthy
human subject (n ¼ 6 per condition,
33–48 years old! young range,
72–81 years old! old range) and in
human liver samples with cirrhosis
and HCC (n ¼ 10 per condition).
C, data are shown as mean  SE of
10 blindly chosen and evaluated
HPF. Bar, 100 mm.  , P < 0.001.
D, stacked bar plots showing the
proportions of overall methylation
of differentially methylated genes
between patients with cirrhosis or
HCC and healthy patients, taken
from four public datasets
(GSE44970, GSE56588, GSE60753,
and TCGA). Red bars represent
hypermethylated genes, whereas
blue bars represent hypomethylated
genes. Color intensity corresponds
to the magnitude of differential
methylation.  , P < 0.001 between
the differences in the ratios of
hypomethylated genes in cirrhosis
and HCC in each dataset.
DNA Hypomethylation and macroH2A1 Synergism in HCC
www.aacrjournals.org Cancer Res; 76(3) February 1, 2016 OF7
Research. 
on January 18, 2016. © 2016 American Association for Cancercancerres.aacrjournals.org Downloaded from 
Published OnlineFirst January 15, 2016; DOI: 10.1158/0008-5472.CAN-15-1336 
and phospho-ATF2 (Thr71): conﬁrming the in silico analysis, an
increased phosphorylation of p38 MAPK and its downstream
effectors was detected in macroH2A1.1 and macroH2A1.2 trans-
genic HepG2 and Huh-7 cells (Supplementary Fig. S8A and
S8C). We then used a selective inhibitor of p38 MAPK activity,
SB202190, at a concentration (10 mmol/L) that is cytostatic in
both cell lines (Supplementary Fig. S9A and S9B), and previ-
ously demonstrated to be effective in inhibiting p38 MAPK in
HCC cells (39). Coincubation of HepG2 or Huh-7 cells with
SB202190 and 5-aza-dC for 72 hours did not affect hyperpho-
sphorylation of p38 MAPK in macroH2A1 isoform transgenic
cells, whereas MSK1 and ATF2 phosphorylation returned to
basal levels, as expected (Supplementary Fig. S8A–S8D).
We then tested the hypothesis that blockade of p38 kinase or
IL8 could hamper IL8 hyperproduction. Coincubation of
HepG2 or Huh-7 cells with SB202190 and 5-aza-dC for 72
hours prevented IL8 hyperproduction in macroH2A1.1-GFP
and macroH2A1.2-GFP transgenic cells compared with control
cells (Fig. 6B and Supplementary Fig. S5B). In contrast, treat-
ment with potent and selective IL8 receptor (CXCR2) antagonist
SB265610 (10 mmol/L; ref. 40) was not effective in blocking the
increase of IL8 levels in macroH2A1.1-GFP and macroH2A1.2-
GFP transgenic cells upon 5-aza-dC treatment (Fig. 6B and
Supplementary Fig. S5B). Thus, IL8 binding to its receptor is
not apparently involved in IL8 secretion. SB202190 and
SB265610 were effective in blocking the macroH2A1.1-GFP–
and macroH2A1.2-GFP–dependent escape from 5-aza-dC–
induced cell senescence as resulted from MTT proliferation
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Figure 4.
Treatment with 5-aza-dC of HepG2 and Huh-7 cell lines stable transgenic for GFP, macroH2A1.1, or macroH2A1.2. A and D, chromatin (C) and nuclear (N)
fractions isolated from untreated HepG2 (A) or Huh-7 (D) cells transgenic for GFP, macroH2A1.1-GFP, or macroH2A1.2-GFPwere processed for immunoblotting with
anti-GFP and total anti-macroH2A1 antibodies. Bands corresponding to macroH2A1-GFP chimeras (70 KD), to the endogenous macroH2A1 (40 KD),
and to GFP (30 KD) are highlighted with red boxes. Histone H3 was used as a marker for the chromatin fraction, whereas negative signal for GAPDH
indicated no cytoplasmic contamination. B and E, HepG2 (B) or Huh-7 (E) cells stably overexpressing GFP were treated with 12 mmol/L 5-aza-dC for 72 hours
and processed for immunoblotting with anti-macroH2A1 and macroH2A1.2 antibodies. Bands corresponding to the endogenous macroH2A1.1 and
macroH2A1.2 (40 KD) are shown. b-Actin was used as a loading control. C and F, assessment of global DNA methylation with LUMA assay in HepG2 (C) and
Huh-7 (F) cell lines, upon 72-hour treatment with 12 mmol/L 5-aza-dC, expressed in a percentage of untreated control. Data were expressed as mean SE of
three independent experiments. , P < 0.01.
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assays (Fig. 6C and Supplementary Fig. S5C) and b-gal staining
(Fig. 6D andSupplementary Fig. S5D). In conclusion,macroH2A1
isoforms might confer resistance to drug-induced senescence
through a p38 MAPK/IL8 mechanism in HCC cell lines.
Redistribution of macroH2A1 isoform genomic occupancy is
largely independent on 5-aza-dC–induced transcriptional
regulation
We sought to analyze if changes in chromatin occupancy by
macroH2A1.1 and macroH2A1.2 might play a role in 5-aza-dC–
induced transcriptional changes. We used ChIP-Seq, using a ChIP
grade anti-GFP antibody, to precipitateGFP andmacroH2A1-GFP
chimeric proteins (Supplementary Fig. S10A). LAMA5andPTPRN
genes were used as positive controls to assess chromatin binding
by qRT-PCR, which showed tight macroH2A1 binding to chro-
matin in macroH2A1.1-GFP and macroH2A1.2-GFP transgenic
cells compared with GFP-expressing cells (Supplementary Fig.
S10B). Full ChIP-Seq raw data are reported in Supplementary
Table S3. 5-aza-dC treatment was associated with differentially
ChIPed genes that were signiﬁcantly more represented in
macroH2A1.1-GFP (449) than in macroH2A1.2-GFP (166)–
overexpressing cells, with only 60 genes in common (Fig. 7A).
AKT3 and STARD8, also known as DLC-3, are shown in Fig. 7B as
examples of HCC-related genes displaying differential binding
with macroH2A1.1-GFP and macroH2A1.2-GFP, respectively,
upon 5-aza-dC treatment. Binding sites were subsequently
grouped by gene section, i.e., 30 or 50 untranslated region (UTR),
coding sequence, intergenic, intron, noncoding, and promoter
(Supplementary Fig. S10C). The frequency of occupancy showed
that macroH2A1.2 binding was enriched in intergenic and pro-
moter regions, and decreased in introns, 50 UTR, and noncoding
regions, whereas macroH2A1.1 binding was decreased in inter-
genic regions and increased in introns (Supplementary Fig. S10C).
Filtering only binding sites that exhibited P values <0.05, Mann–
Whitney P values <0.1, and differential scaled changes of at
least 0.5-fold between 5-aza-dC–treated and –untreated cells,
and further selecting genes that were differentially expressed
(>1.5-fold) at the mRNA level between 5-aza-dC–treated
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Figure 5.
5-aza-dC–induced senescence and growth inhibition in HepG2 (A–D) and Huh-7 cells (E–H) transgenic for GFP, macroH2A1.1-GFP (macroH2A1.1), or
macroH2A1.2-GFP (macroH2A1.2) following treatment with 12 mmol/L 5-aza-dC for 72 hours. A and E, b-gal staining of HepG2 (A) and Huh-7 (E) cells. Nuclei
were counterstained with DAPI. Images were taken under bright light for b-gal and with respective channels for DAPI (blue) and GFP (green). B and F,
positive cells for b-gal staining as in A and E were counted and represented as a proportion of the total. Results are expressed as mean  SE of three experiments.
C and G, MTT assay in HepG2 (C) and Huh-7 (G) cells after 72 hours with (black columns) or without (gray columns) 5-aza-dC incubation; percentage
growth compared with untreated GFP control cells. D and H, scratch migration assay in HepG2 (D) and Huh-7 (H) cells. Left, representative images taken at 0 and
72 hours after scratching. Right, software-assisted quantiﬁcation of wounded areas expressed as a percentage of the initial scratch. All data were expressed
as mean  SE of three independent experiments.  , P < 0.05;  , P < 0.01; and  , P < 0.001.
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and –untreated cells, we obtained only 28 and 9 genes for
macroH2A1.1 and macroH2A1.2, respectively, involved in nutri-
ent metabolism and cancer pathways (Circos plot, Fig. 7C). Our
genomic analysis thus demonstrated that 5-aza-dC treatment
induces modest changes in macroH2A1.1 and macroH2A1.2
genome occupancy that may not account for its transcriptional
effects in HCC cells.
Discussion
In this study, we describe a new epigenetic synergism between
the histone variant macroH2A1 and DNA methylation, control-
ling the escape of HCC cells from drug-induced senescence. HCC
frequently involves genome-wide DNA hypomethylation accom-
panied by focal promoter hypomethylation and heterochroma-
tinization. Interestingly, global DNA hypomethylation is also a
characteristic of most aging tissues, with the exception of the liver
(41). Our data in healthy old versus young murine and human
liver specimens conﬁrm these ﬁndings. Focal DNA methylation
signatures have been used as biomarkers of HCC (20), and of
healthy liver aging progression (42). The liver is an ideal tissue to
study the epigenetic mechanisms that control cell fate toward
healthy aging or cancer. We focused on emerging epigenetic
players in tumorigenesis, the exon-spliced isoforms of histone
variant macroH2A1—macroH2A1.1 and macroH2A1.2 (13)—
and their interplay withDNAmethylation during aging andHCC.
Although macroH2A1.1 acts as a tumor suppressor in many
cancer types, the role of macroH2A1.2 is context-dependent
(10). MacroH2A1.1 and macroH2A1.2 are dramatically and
equally upregulated in HCC (3), reﬂecting the lack of linearity
in macroH2A1 pre-mRNA splicing processes identiﬁed in HCC
versus adjacent normal liver tissues (43). The whole macroH2A1
gene acts synergistically with 5-aza-dC–induced DNA demethyl-
ation to silence the tumor suppressor and senescence marker p16
in ﬁbroblasts (25). We found that an increased expression of
macroH2A1 isoforms is associated to senescence marker b-gal
staining in human HCC tissue. Protein levels of macroH2A1
isoforms were also signiﬁcantly increased without changes in
5-methyl cytosine positivity in the liver of old mice and humans.
To study the functional interplay between the macroH2A1 iso-
forms, HCC-associated DNA hypomethylation, and senescence/
HCC aggressiveness, we established HepG2 and Huh-7 HCC cell
lines expressing GFP-, macroH2A1.1-GFP-, and macroH2A1.2-
GFP transgenes. Consistent with previous reports (21–24), incu-
bation of HepG2 andHuh-7 cells with DNA-demethylating agent
5-aza-dC induced a senescent-like phenotype, characterized by
b-gal staining, reduced proliferation, and migration. Overexpres-
sion of either macroH2A1.1 or macroH2A1.2 counteracted this
drug-induced senescent-like phenotype. In addition, macroH2A1
isoform activity induced a decrease in b-gal staining and an
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Figure 6.
macroH2A1.1 and macroH2A1.2 counteract 5-aza-dC–induced HepG2 cell senescence in a p38 MAPK/IL8-dependent manner. A, the protein levels of SASP
effectors sICAM, IL1b, IL6, and IL8 were assessed in the supernatant of HepG2 cells with or without 12 mmol/L 5-aza-dC for 72 hours with a customized human
MILLIPLEX MAP (multi-analyte panels) Luminex system. B, IL8 levels were assessed in the supernatant of HepG2 cells with or without 12 mmol/L 5-aza-dC
for 72 hours, and in the presence or absence of selective p38 MAPK inhibitor (SB202190; 10 mmol/L) or IL8 receptor antagonist (SB265610; 10 mmol/L), with a
MILLIPLEX Luminex System. C, MTT assay in HepG2 cells after 72 hours with (black columns) or without (gray columns) 5-aza-dC incubation; percentage
growth compared with untreated GFP control cells in the presence or absence of p38 MAPK inhibitor (SB202190; 10 mmol/L) or IL8 receptor antagonist
(SB265610; 10 mmol/L). D and E, b-gal staining of HepG2 cells upon 5-aza-dC treatment (12 mmol/L for 72 hours) in combinationwith SB202190 (10 mmol/L; D) or
in combination with SB265610 (10 mmol/L; E). Nuclei were counterstained with DAPI. Images were taken under bright light for b-gal and with respective
channels for DAPI (blue) and GFP (green). All data were expressed as mean  SE of three independent experiments.  , P < 0.05; , P < 0.01; and  , P < 0.001
versus control untreated GFP-expressing cells. $, P < 0.05 and $$$, P < 0.001 versus control GFP-expressing cells treated with 12 mmol/L 5-aza-dC for 72 hours.
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increase in antisenescence gene expression in mouse HCC cells
(Hepa1-6), indicating a potential evolutionarly conserved mech-
anism. Conversely, KD of the macroH2A1 gene slowed cell
proliferation and migration compared with control HCC cells.
However, KO of macroH2A1 in old mice or KD in 5-aza-dC–
treated HepG2 cells had no effects on global DNA methylation
and senescencemarkers.MacroH2A1 function is thus dispensable
for age- and drug-induced senescence. The cellular response to
DNA hypomethylation is variable. In part, the affected genomic
region dictates the cellular response to loss of DNA methylation:
hypomethylation of gene regulatory regions, such as promoters,
can remove gene repression, whereas hypomethylation of repet-
itive elements can reduce heterochromatin formation and pro-
mote genomic instability. Our data show that transgenic expres-
sion of macroH2A1.1 or macroH2A1.2 in HepG2 and in Huh-7
cells paradoxically synergized with 5-aza-dC to induce a decre-
ment in DNA genome-wide methylation. Further studies are
needed to determine which genomic regions are selectively
demethylated by macroH2A1 overexpression or by DNA-
demethylating drugs in HCC; interestingly, in colorectal cancer
cells, 5-aza-dC targets genomic DNA, whereas promoter CpG
island methylation remains unchanged (44).
In HCC cells, 5-aza-dC–induced senescence was not accom-
panied by activation of the classic regulator of senescence p16,
p21, and p53. Instead, we report SASP activation, consistent
with previous studies (21). Among SASP cytokines/chemo-
kines, IL8 expression displayed a 2-fold increase in protein
levels in cells transgenic for macroH2A1 isoforms upon 5-aza-
dC treatment. macroH2A1 was recently shown as a critical
component of the feedback loop that maintains SASP in onco-
gene-induced senescence (45). Our RNA-Seq showed that cells
transgenic for macroH2A1 isoforms displayed higher levels of
mRNAs involved in oncogenesis than cells depleted of
macroH2A1. In detail, IPA indicated a strong enrichment of
Figure 7.
Representation of commonly and
differentially bound genes in ChIP-Seq
data. A, Venn diagram of differentially
bound genes for macroH2A1.1 þ 5-aza-
dC versus CTL-GFP þ 5-aza-dC and
macroH2A1.2 þ 5-aza-dC versus
CTL-GFP þ 5-aza-dC HepG2 stable cell
lines. B, modiﬁed Partek Genome
Browser view of two representative
gene bodies differentially bound
(assessed as differential coverage of
peaks) by macroH2A1.1 (AKT3) and by
macroH2A1.2 (STARD8) following
5-aza-dC treatment. Boxes indicate
gene regions of signiﬁcant differential
binding. C, representation of
differentially expressed and
differentially bound genes and their
common pathways in macroH2A1.1-
overexpressing (left) and macroH2A1.2
transgenic (right) HepG2 cells. The
outer circle shows the genomic
positions of genes. Heatmaps represent
fold change values of RNA-Seq (red)
and ChIP-Seq (blue). Blue heatmaps
illustrate the binding strength of
macroH2A1 isoforms in untreated cells
(outer) and following 5-aza-dC
treatment (inner) in HepG2 cells. Genes
are linked by colored edges based on
their involvement in cancer, metabolic,
and inﬂammatory pathways. Genes
belonging to the ﬁrst group are linked in
red; genes belonging to the ﬁrst and
second groups are linked in dark green.
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transcripts involved in p38 MAPK activation and subsequent
IL8 protein production in HCC cells transgenic for macroH2A1
isoforms. p38 MAPK signaling activation was conﬁrmed by
immunoblotting. p38 MAPK and IL8 are implicated in HCC
aggressiveness and metastatic potential (46, 47). Our ﬁndings
using highly selective inhibitors of p38 MAPK activity and IL8
receptor activation showed that blockage of either pathway is
sufﬁcient to dampen the antisenescence effect of macroH2A1
isoforms. Furthermore, IL8 production by macroH2A1 trans-
genic HCC cells was dependent on p38 MAPK signaling, a
mechanism previously identiﬁed for IL8 production in immune
cells (48). Campisi's laboratory demonstrated that p38 MAPK
activity is necessary and sufﬁcient to regulate SASP, indepen-
dently of p53 and p21, as in our study, upon a variety of
senescence-inducing stresses (49).
Despite having transcriptional and genomic patterns partially
overlapping,macroH2A1 isoforms trigger a similar escape from5-
aza-dC–induced tumor suppression. Our computational analysis
revealed a very limited number of genes with different mRNA
levels in 5-aza-dC–treated and –untreated cells that were differ-
entially bound by either one or other of the isoforms. This might
suggest indirect oncogenic/SASP transcriptional programs inde-
pendent of changes in macroH2A1 genomic occupancy. Varia-
tions in macroH2A1 transcriptional activities without changes in
genome occupancy have been reported in breast cancer cells (8).
In summary, our data indicate that macroH2A1 might be a
simple bystander in the liver of the healthy elderly, and it might
not be of use to counteract age-associated senescence in the
absence of DNA demethylation. Conversely, macroH2A1 could
be both a powerful tissue biomarker to stratify HCC patients (3)
and a new target to implement SASP- and chemotherapy-based
therapeutic opportunities (24, 38, 45).
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